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PPercutaneous Pacemaker and Implantable
Cardioverter-Defibrillator Lead Extraction in
100 Patients With Intracardiac Vegetations
Defined by Transesophageal Echocardiogram
Jon A. Grammes, DO,* Christopher M. Schulze, DO,* Mohammad Al-Bataineh, MD,*
George A. Yesenosky, MD,* Christine S. Saari, MSN, CRNP,* Michelle J. Vrabel, MSN, CRNP,*
Jay Horrow, MD, MS,† Mashiul Chowdhury, MD,‡ John M. Fontaine, MD,* Steven P. Kutalek, MD*
Philadelphia, Pennsylvania
Objectives We describe the feasibility, safety, and clinical outcomes of percutaneous lead extraction in patients at a tertiary
care center who had intracardiac vegetations identified by transesophageal echocardiogram.
Background Infection in the presence of intracardiac devices is a problem of considerable morbidity and mortality. Patients
with intracardiac vegetations are at high risk for complications related to extraction and protracted clinical
courses. Historically, lead extraction in this cohort has been managed by surgical thoracotomy.
Methods We analyzed percutaneous lead extractions performed from January 1991 to September 2007 in infected patients
with echocardiographic evidence of intracardiac vegetations, followed by a descriptive and statistical analysis.
Results A total of 984 patients underwent extraction of 1,838 leads; local or systemic infection occurred in 480 pa-
tients. One hundred patients had intracardiac vegetations identified by transesophageal echocardiogram, and all
underwent percutaneous lead extraction (215 leads). Mean age was 67 years. Median extraction time was 3
min per lead; median implant duration was 34 months. During the index hospitalization, a new device was im-
planted in 54 patients at a median of 7 days after extraction. Post-operative 30-day mortality was 10%; no
deaths were related directly to the extraction procedure.
Conclusions Patients with intracardiac vegetations identified on transesophageal echocardiogram can safely undergo com-
plete device extraction using standard percutaneous lead extraction techniques. Permanent devices can safely
be reimplanted provided blood cultures remain sterile. The presence of intracardiac vegetations identifies a sub-
set of patients at increased risk for complications and early mortality from systemic infection despite device ex-
traction and appropriate antimicrobial therapy. (J Am Coll Cardiol 2010;55:886–94) © 2010 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.034f
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candmark trials have expanded the indications for cardiac
hythm management (CRM) devices (1–4). The conse-
uences of device-related complications are well docu-
ented (5–8). Infection of CRM devices has been reported
n 0.8% to 19.9% of patients (9). Mortality rates for
ntreated patients are as high as 66% compared with 18%
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edical in device implants; is on the Speakers’ Bureau of Medtronic; and has received
ractice development support from Boston Scientific. Dr. Horrow is an employee of
straZeneca LP. Dr. Kutalek is a consultant for Spectranectics Co.o
Manuscript received August 6, 2008; revised manuscript received October 7, 2009,
ccepted November 2, 2009.or patients treated with antibiotics and device removal
5,7,8,10–12). Eradication of device-related infection re-
uires complete system removal, given the morbidity and
ortality associated with antibiotics alone or partial device
emoval (5,7,11,13–16).
See page 895
Patients with infected devices and intracardiac vegeta-
ions represent a high-risk population, the incidence of
hich is difficult to determine from available studies. Arber
t al. (17) documented the incidence of endocarditis with
evice infection to be 9.4%. Patients with vegetations 1
m have historically been managed with extraction through
pen thoracotomy due to potential for septic embolization
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March 2, 2010:886–94 Lead Extraction in Patients With Endocarditisnd hemodynamic compromise (6,10,14,18–20). A review
f the literature reveals limited data describing the
fficacy and safety of percutaneous lead extraction in this
ubset (6,14,19 –21).
In this study, we document the incidence of intracardiac
egetations in patients with CRM devices referred to an
xtraction center and evaluate the safety and efficacy of lead
xtraction in this high-risk population. Further, we examine
he safety and clinical outcomes associated with reimplan-
ation of a new CRM device.
ethods
tudy population. Our institution’s institutional review
oard approved the study. A comprehensive database is
aintained for all patients undergoing lead extraction.
atients who had objective evidence of device-related infec-
ion and echocardiographic evidence of intracardiac vegeta-
ions and underwent device extraction at our institution
rom January 1991 to September 2007 were included in this
tudy. Office charts and hospital records were reviewed to
ather pertinent clinical information.
ontrol population. All patients who underwent lead
xtraction in 2004 without evidence of intracardiac vegeta-
ions served as a reference population. We compared im-
lant duration and extraction times between the 2004
ohort and our study population. To standardize compari-
ons, only data from the first lead extracted in each patient
ere used.
efinitions. Device-related infection was defined by signs
f local pocket inflammation, generator or lead erosion, or
ositive blood cultures. Device-related endocarditis was
efined according to the modified Duke criteria (22).
atients with a diagnosis of definite or possible endocarditis
ere included. Intracardiac vegetation was defined as a
iscrete, echogenic, oscillating mass found on a valve, lead,
r endocardial surface and confirmed in multiple views by
chocardiography. Echocardiograms were reviewed by an
chocardiographer and electrophysiologist to determine
egetation size and location and to distinguish true vegeta-
ion from false echodensities. In 23 cases, echocardiogram
mages were not available for review and information was
btained from study reports.
Implant duration was the time between initial lead implan-
ation to the time it was extracted. Lead extraction time was
efined as the duration from the time when the head of the
ead was cut off until its complete removal. Extraction time for
eads removed with traction only was the time from removal of
he anchoring sleeve to complete removal.
urrent protocol. Because of potential for septic emboli-
ation, pre-operative transesophageal echocardiography
TEE) is used to risk stratify patients. After extraction,
EE is performed in all patients before device reimplanta-
ion. In addition, intraoperative intracardiac echochar-
iography (ICE) may be used to assess lead fibrosis and
egetation stability and to monitor for complications. All
atients undergo serial blood cultures and intravenous mntibiotic therapy according to
ensitivities of isolated organisms
nd the recommendations of an
nfectious disease consultation.
emporary transvenous pacing
ires are placed when indicated
espite presence of vegetations
ntil a permanent system can
afely be implanted.
Standard methods for percuta-
eous lead extraction are utilized
t the discretion of the extracting
hysician (20,23–28). An elec-
rosurgical dissection sheath (Cook
orp., Vandergrift, Pennsylvania)
r Excimer laser (Spectranetics
orp., Colorado Springs, Colorado)
s used to extract heavily fibrotic
eads. Extensive surgical debride-
ent of the pocket is performed
sing electrocautery and blunt dis-
ection. Timing of device reim-
lantation is based primarily on sterility of blood cultures, but
lso on resolution of vegetations. Reimplantation is usually
erformed on the contralateral side. In select cases, an ipsilat-
ral lateral subpectoral location may be used depending on the
xtent of pocket infection.
Patients are followed up in the outpatient office after extraction.
n cases when patients were referred back to their primary
nstitution, the primary cardiologist or internist was contacted
or information regarding the patient’s medical progress.
tatistical analysis. Mean and SD and/or median and
nterquartile ranges (IQRs) summarize continuous demo-
raphic data. The Wilcoxon test compares implant durations
nd extraction times in the study population to those of the
004 reference population. Kaplan-Meier curves and product-
imit life-table estimates analyzed the time from lead extraction
o reimplantation of a new lead, stratified into groups by
icroorganism type. Both log-rank and Wilcoxon tests were
sed to compare those groups with respect to time to reim-
lantation. All analyses used a significance level of 0.05.
esults
tudy population. Figure 1 represents the patients referred
or lead extraction from January 1991 through September
007. Nine hundred eighty-four patients underwent extrac-
ion, and 1,838 leads were removed. Four hundred eighty
atients (49%) required device extraction of 1,000 leads for
ystemic or localized pocket infection. One hundred pa-
ients had echocardiographic evidence of intracardiac vege-
ations (Figs. 2A and 2B), and they represent 10% of our
otal extraction population (Table 1). Vegetations were
ound on leads in 56 cases and valves in 35 cases; in 9 cases,
his information was not available. Vegetations ranged in
ize from 0.2 to 4.0 cm in largest longitudinal diameter; the
Abbreviations
and Acronyms
CI  confidence interval
CNSS  coagulase-
negative Staphylococcus
species
CRM  cardiac rhythm
management
ICE  intracardiac
echocardiography
IQR  interquartile range
MRSA  methicillin-
resistant Staphylococcus
aureus
MSSA  methicillin-
sensitive Staphylococcus
aureus
SCD  sudden cardiac
death
TEE  transesophageal
echocardiogramean diameter was 1.6 cm. All patients underwent com-
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Lead Extraction in Patients With Endocarditis March 2, 2010:886–94lete device extraction in our electrophysiology laboratory;
15 leads were removed using standard percutaneous tech-
iques. No patients required surgical extraction. Seventy-
ne patients were men. Mean age was 67  15 years (age
ange 22 to 92 years).
icrobiology. Figure 3 depicts the infectious pathogens
solated from cultures. The most common infectious organ-
sms were methicillin-resistant Staphylococcus aureus
MRSA) and methicillin-sensitive Staphylococcus aureus
MSSA), isolated from 34 and 25 cultures, respectively.
ther organisms included coagulase-negative Staphylococcus
pecies (CNSS) (n  14), Enterococcus faecalis (n  4),
treptococcus species (n  4), vancomycin-resistant Entero-
occus (n 1), Citrobacter (n 1), and Candida species (n
). Sixteen patients had negative blood cultures despite
aving evidence of endocarditis. Five of these patients had
ocket tissue cultures that were positive, including MRSA
n 1 patient, MSSA in 2 patients, and CNSS in 2 patients.
mplant duration and extraction times. Implant duration
n the study population ranged from 1 to 300 months (mean
0.9  52.8 months, median 32.5 months, IQR 61
onths). Extraction times ranged from 1 to 187 min (mean
1.2  21.9 min, median 3 min, IQR 13 min). Implant
uration for the first lead extracted from each patient in the
tudy population, 54.4  56.8 months (median 34 months,
QR 68.5 months, n  99), did not differ from that of the
004 reference population, 40.2  45.3 months (median 24
onths, IQR 36.5 months, n 66; p 0.095 by Wilcoxon
est). Extraction time for the study population, 10.8  16.8
in (median 4 min, IQR 15 min, n  99), did not differ
rom that of the reference population, 5.3  6.3 min
median 1 min, IQR 6 min, n 66; p 0.067 by Wilcoxon
est).
eimplantation of a new device. Fifty-four (54%) patients
Figure 1 Extraction Population
Total number of patients and leads from January 1991 to September 2007, includere reimplanted with a new device during hospitalization sFig. 4). Two of these patients underwent reimplantation of
picardial systems due to persistent vegetations. Median
ime to reimplantation was 7 days (mean 11 days). Life-
able analysis of time to reimplantation disclosed median
imes of 7 (95% confidence interval [CI]: 6 to 16) days for
atients with negative blood cultures, 8 (95% CI: 7 to
ndefined) days for patients whose culture results were
ositive for CNSS, 13 (95% CI: 7 to 27) days for MSSA,
nd 14 (95% CI: 7 to 60) days for MRSA. The undefined
pper limit for CNSS was obtained from a final censored
bservation. Both the log-rank test (p  0.3096) and the
ilcoxon test (p  0.5120) demonstrated no impact of
ulture result on time to reimplantation.
ollow-up and clinical outcomes. Follow-up was avail-
ble for 71 patients (Fig. 5). Twenty-nine patients were lost
o follow-up because of their diverse locations of origin. The
verage follow-up was 438 days (median 150 days).
Forty-six patients were not reimplanted during the hos-
italization. Four patients were transferred back to their
rimary institution after device extraction. Eighteen pa-
ients were not reimplanted because of persistent systemic
nfection. Two patients refused reimplantation despite a
edical indication, and 2 patients were referred to hospice.
ne patient was not reimplanted because of metastatic
ancer. Of the remaining 19 patients, 18 had no compelling
ndication to reimplant a permanent device. Extensive
hrombosis of bilateral subclavian veins limited access in the
ther patient. Thirty-nine of the 46 patients (85%) were
ischarged in stable condition. Seven patients died during
he index hospitalization, and 1 experienced a complication
uring lead extraction; these patients are discussed in the
ollowing text.
Fifty-four patients underwent subsequent device reim-
lantation. Fifty-one patients (94%) were discharged in
bsets with device-related infection and intracardiac vegetations.ing sutable condition. During follow-up, no patient had clinical
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March 2, 2010:886–94 Lead Extraction in Patients With Endocarditisndicators of relapsing infection that required a second
xtraction. Three patients died during the index hospital-
zation and 4 others had complications during lead extrac-
ion; these patients are discussed in the following text.
orbidity and mortality. Of the 71 patients who had
ong-term follow-up available, 19 patients died (27%). Ten
atients died during the index hospitalization, and 9 died
fter being discharged. Eleven patients (59%) died of
ersistent septicemia, 1 patient died of SCD, and 7 patients
ied of unknown causes but had no evidence of ongoing
epsis during follow-up. Four patients died after being
eimplanted with a new device despite having sterile blood
ultures and no vegetations on repeat TEE. Post-operative
0-day mortality was 10% (Table 2).
Five patients had complications during lead extraction.
wo patients had embolization of the vegetation. In 1 of
hose patients, embolization occurred during attempts to
nare a large vegetation before lead removal. The patient
emained hemodynamically stable but had chest pain after
he procedure. High-resolution computed tomography
Fig. 6) revealed a filling defect in the pulmonary artery.
Figure 2 ICE and TEE of Lead Vegetation
(A) Intracardiac echocardiogram (ICE) shows vegetations attached to both right
ventricle (RV) and right atrium (RA) leads. (B) Transesophageal echocardiogram
(TEE) of lead vegetation attached to the RV lead as it crosses the tricuspid
valve. The approximate diameter is 2.4 cm. LA  left atrium.he patient underwent uncomplicated device reimplanta-ion 8 days later. A third patient required an additional
rocedure to snare a lead fragment that embolized to the
ulmonary artery during the initial extraction. The lead was
5 years old and was completely removed in pieces because
f its brittle condition. The patient experienced no clinical
ymptoms and underwent reimplantation 7 days later. A
ourth patient had severe tricuspid regurgitation due to a
ail posterior leaflet that was not present before extraction.
fifth patient had hypotension after extraction that re-
uired vasopressor support for 24 h. Subsequent echocar-
iogram was unrevealing, and the patient had a new device
mplanted 12 days later. All 5 patients were discharged in
table condition and had uneventful clinical follow-up.
iscussion
he management of device-related infection is well
escribed, but considerable variability exists in regional
anagement strategy. Complete hardware removal is
ssential to eradicate infection and prevent relapsing
acteremia. In 9 retrospective studies, the mortality rate
as 41% for patients treated with antibiotics alone
ompared with 19% for patients receiving antibiotics and
omplete device removal (28).
Patients with device-related infection and intracardiac
egetations 1 cm have historically undergone surgical
horactomy for device removal because of the potential for
eptic embolization. Literature supporting this management
pproach is limited (6,14,28,29). Our single-center experi-
nce involving this high-risk population suggests that stan-
ard endovascular percutaneous extraction of leads is both
easible and safe.
ncidence of intracardiac vegetations. The incidence of
ntracardiac vegetations comprised 10% of our entire
xtraction population and 21% of all patients with device-
elated infection. The incidence is greater than that
ound in earlier studies (17) but is comparable to recent
tudies that describe endocarditis in 20% to 25% of
evice-related infections (30,31). The incidence will vary
ccording to the institution’s referral characteristics, how
evice-related endocarditis is defined, as well as imaging
odalities utilized. For the purpose of this study, we
ncluded patients with clinically definite or possible
ndocarditis by modified Duke criteria. The 16 patients
ho were classified as possible endocarditis had evidence
atient PopulationTable 1 Patient Population
Patients, n 984
Leads extracted, n 1,838
Patients infected, n (% of all patients) 480 (49)
Infected leads, n (% of all leads) 1,000 (54)
Infected patients with vegetation, n 100
Percent of total patients 10
Percent of infected patients 21
Infected leads from patients with vegetation, n 215
Percent extracted leads 12Percent infected leads 22
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Lead Extraction in Patients With Endocarditis March 2, 2010:886–94f vegetations but only clinically local infection with
egative blood cultures. Without pathologic verification,
hese masses could represent fibrous casts or thrombus;
owever, the incidence of culture-negative endocarditis is
5% to 7%, and cultures preceded by antibiotics may be
egative in as many as 14% of cases (32). Given the
requent ambiguity of initial culture data, we believe it is
mportant to image all infected patients undergoing
evice extraction to identify high-risk patients and curtail
uture infection relapses.
Figure 3 Microbiology of Infected Devices
Organisms isolated from blood cultures. “Others” include Candida species, Citrob
Figure 4 Reimplantation Time
Number of days to reimplantation of a new device.easibility. All leads were successfully removed using a
ercutaneous approach. Implant duration and extraction
ime between the study group and the reference population
ere not significantly different. In fact, there was a trend
oward shorter extraction times in patients with vegetations.
his finding likely reflects improvement in extraction tech-
iques and operator experience over time. Although we did
ot compare variables such as lead fixation mechanism or
egree of fibrosis, our data suggest that the presence of
ntracardiac vegetations does not prolong extraction time.
and Streptococcus species.acter,
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March 2, 2010:886–94 Lead Extraction in Patients With EndocarditisOur data parallel the 93% to 97% percutaneous extraction
uccess rates reported in other large cohorts (28,33–34).
maller studies involving patients with endocarditis also doc-
ment successful percutaneous extraction (14,15,30,35).
eier-Ewert et al. (30) successfully removed leads in 9 patients,
nd Victor et al. (15) removed leads in 9 of 12 patients; all
egetations were1 cm. Massoure et al. (35) removed leads with
mean vegetation size of 1.3 cm in 36 of 37 patients.
One patient required a femoral approach using the Byrd
orkstation to snare a lead fragment that embolized to the
ulmonary artery. Using the needle’s eye snare or the Dotter
asket Retrieval System (Cook Vascular, Leechburg, Penn-
ylvania) in combination with countertraction is a well-
escribed alternative (36–39). Published series from Klug et
l. (36) and Espinosa et al. (38) have reported success rates
f 87.2% and 82%, respectively.
Our data support the idea that a percutaneous lead
xtraction in patients with intracardiac vegetations has a
igh success rate and that leads can be removed in their
ntirety using standard techniques.
ortality and morbidity. In our study the post-operative
0-day mortality was 10%. Although a standard measure of
urgical outcomes, post-operative mortality may not reflect
rocedural mortality. The 10 patients who died had multi-
le comorbidities and overwhelming sepsis; their deteriora-
Figure 5 Clinical Follow-Up
Clinical outcomes after device extraction. *Survived index hospitalization. †Died dion was secondary to the natural progression of disease. rne patient was transferred from an outside hospital on
asopressor support with septic shock. Although the device
as extracted without incident, the patient died later that
ay after unsuccessful resuscitation. All other deaths oc-
urred at least 5 days after extraction and were not a result
f embolized vegetations or from the extraction procedure.
hese unfortunate outcomes occurred in a critically ill
ubset of patients who often have extensive comorbidities.
The overall mortality for percutaneous lead extraction
eported from large databases or single centers with expe-
ienced operators is low. Mortality rates range from 0.1% to
.6% and major complication rates range from 1.4% to 1.9%
20,27,33,34). Data regarding operative mortality for pa-
ients with intracardiac vegetations is less robust. Klug et al.
14) reported a mortality rate before discharge of 7.6% and
n overall mortality of 26.9% at 20 months. Further, Victor
t al. (15) reported deaths of 3 of 14 patients (21%) who
nderwent percutaneous lead extraction. Most recently,
ohail et al. (31) reported deaths of 9 of 189 patients (5%).
nly 44 patients in that study had endocarditis; 5 of those
atients died, yielding a mortality rate of 11%. All patients
n our study had intracardiac vegetations. We believe that
he 10% 30-day operative mortality rate in our series reflects
everity of disease rather than the mode of extraction.
Depending on the definitions used, major complication
ndex hospitalization.uring iates reportedly range from 0.4% to 1.4% (33,34). Sohail et
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Lead Extraction in Patients With Endocarditis March 2, 2010:886–94l. (31) reported 20 patients (11%) who had complications
fter percutaneous extraction, but they are not categorized
ccording to definitions published in previous guidelines.
imited data are available regarding complications during
ercutaneous lead extraction in patients with intracardiac
egetations. In our experience, 5 patients had complications
elated to the procedure, but none could be classified as
ajor. We believe this is an acceptable complication rate
ost-Operative 30-Day MortalityTable 2 Post-Operative 30-Day Mortality
Patient #
Vegetation
Size (cm)
Death After
Explant (days) Brief Clinical Summary
1 1.0 5 Device reimplanted but severe
Enterococcus sepsis persisted with
subsequent VDRF, ARF, and MOSF
2 2.9 21 Developed diffuse purulent
lymphadenopathy and bilateral
pneumonia; MSSA sepsis with
septic emboli found at autopsy
3 NA 18 Fever, hypotension, and MRSA sepsis
4 NA 15 Treated for sepsis; post-extraction
transesophageal echocardiogram
revealed persistent mitral valve
vegetation and right atrial mass.
Transferred to skilled nursing
facility 8 days later; died 1 week
later of presumed septicemia
5 1.8 5 Initial device extraction without
incident, new device reimplanted
4 days later; found unresponsive 1
day later; echocardiogram
negative for tamponade; ACLS
initiated for PEA code was
unsuccessful
6 3.0 0 Transferred from outside facility on
multiple pressors from septic
arthritis that seeded device; was
coagulopathic, which was reversed
before extraction; worsening
hypotension after procedure
despite pressors; ACLS initiated
but unsuccessful
7 2.2 14 MSSA sepsis with multiorgan failure;
VDRF; ARF developed requiring
HD; pseudomembranous colitis on
multiple vasopressors; withdrawal
of care
8 NA 12 Encephalopathic after procedure with
hepatic failure; ARF requiring HD;
hypotensive requiring multiple
vasopressors; withdrawal of care
9 1.4 10 Had prosthetic valve endocarditis
with perivalvular dehiscence;
overwhelming sepsis developed
with multiorgan failure, ARF
requiring dialysis, atrial fibrillation,
VDRF; withdrawal of care
10 1.5 20 Discharged from hospital with
LifeVest; reportedly found
unconscious at home and
pronounced dead on arrival at
hospital
CLS  advanced cardiac life support; ARF  acute renal failure; HD  hemodialysis; MOSF 
ultiorgan system failure; MRSA  methicillin-resistant Staphylococcus aureus; MSSA 
ethicillin-sensitive Staphylococcus aureus; NA  not applicable; PEA  pulseless electrical
ctivity; VDRF  ventilator-dependent respiratory failure.iven the high-risk nature of the population.otential for pulmonary embolization. A concern for
eptic embolization in patients with large vegetations 1
m is documented in the literature (14,15,19,30). Studies
nvolving right-sided endocarditis have documented an
ncreased risk of embolization with larger vegetations but
emonstrate an excellent prognosis and no detrimental
mpact on survival (35,40,41). Klug et al. (14) reported a
re-operative incidence of embolization, confirmed by
entilation-perfusion scans, in as many as 34% of patients.
eier-Ewert et al. (30) found evidence of pulmonary
mbolism in 5 of 9 patients (55%) by scintigraphic scans.
ospital stay for these patients was not statistically pro-
onged compared with patients without embolism.
In our experience, only 2 patients experienced witnessed
mbolization of vegetation material, which measured 2
m before extraction in both cases. A third patient had
resumptive embolization of a vegetation measuring 1.2 cm
fter extraction, and experienced transient hemodynamic
hanges requiring brief vasopressor support. All 3 patients
ade a full recovery and were discharged home. It is
onceivable that septic embolization may have caused the
Figure 6 High-Resolution CT Angiography
High-resolution computed tomography (CT) angiography indicates (A) a filling
defect in the right middle pulmonary artery (red arrow), consistent with septic
pulmonary embolism, and (B) a filling defect in the right atrium (red arrow) at
the junction with the superior vena cava, consistent with retained vegetation.
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March 2, 2010:886–94 Lead Extraction in Patients With Endocarditiseath of 1 patient who died the day of extraction; however,
er clinical deterioration prevented any confirmatory imag-
ng, and she was overwhelmingly septic before the proce-
ure. Routine imaging was not performed in this series, but
iven the aforementioned studies and the frequent absence
f vegetations seen on post-operative imaging, the incidence
f silent embolism is likely higher. Although embolization
epresents a potential complication and is likely underesti-
ated in our experience, our data suggest that the majority of
atients with vegetations up to 4 cm in size can safely undergo
ercutaneous lead extraction without clinical compromise.
ethod of extraction. Historically, patients with intracar-
iac vegetations have preferably been managed by surgical
pproaches to directly visualize lead removal and limit the risk
f lead fragmentation, tricuspid valve damage, and septic
mbolization that occurs with percutaneous techniques. In
hese situations, success with conventional median sternotomy
ith or without cardiopulmonary bypass as well as the limited
triotomy approach is well described (14,28,29,42,43). Unfor-
unately, there remains significant morbidity and mortality due
o the invasive nature and prolonged recovery times, with
ortality rates ranging from 12.5% to 40% (20,28,29). No
tudy to date directly compares surgical and percutaneous
pproaches, and data are limited in patients with intracardiac
egetations. Table 3 compares mortality rates for both surgical
nd percutaneous techniques.
tudy limitations. Our experience represents that of a ter-
iary care referral center. Results at centers without comparable
xperience with lead extraction may differ. Further, standard-
iterature Review of Surgical and Percutaneous Lead Extraction MTable 3 Literature Review of Surgical and Percutaneous Lead E
First Author, Year
(Ref. #) n
Extraction
Approach*
Post-Operative
Mortality, % (n)
Maj
Complica
Brodman, 1992 (18) 11 Surgical 9% (1) NA
Frame, 1993 (10) 13 Surgical 15% (2) NA
Klug, 1996 (14) 12‡ Surgical 16.6% (2) NA
38‡ Percutaneous
Cacoub, 1998 (28) 29‡ Surgical 12.4% (4) NA
4‡ Percutaneous
Byrd, 1999 (33) 2,338 Percutaneous 0.4% 1.6
Victor, 1999 (15) 9‡ Surgical 11% (1) NA
14‡ Percutaneous 21% (3)
Byrd, 2002 (44) 1,684 Percutaneous 0.8% (13) 1.9
del Rio, 2003 (29) 5‡ Surgical 40% (2) 40
25‡ Percutaneous 4% (1) 8
Meier-Ewert, 2003 (30) 9‡ Percutaneous 11% (1) NA
Massoure, 2007 (35) 20‡ Surgical 5.3% (3) NA
37‡ Percutaneous
Sohail, 2007 (31) 19 Surgical 5.3% (1) 26
166 Percutaneous 0.6% (1) 12
Camboni, 2008 (45) 21 Surgical 9.5% (2) 14
53 Percutaneous 0% 6
Jones, 2008 (34) 485 Percutaneous 0% 0.4
Surgical extraction performed through median sternotomy or right atriotomy with or without ca
omplications as published in prior guidelines (42). ‡Patients met criteria for definite or possible device-
IE  infective endocarditis; IH  index hospitalization; NA  not applicable (study did not report surgiczation of post-operative care and long-term follow-up is
imited as many patients were referred back to their primary
nstitution. The true incidence of intracardiac vegetations may
e overestimated because of our referral bias and the method
sed to define endocarditis. Although the modified Duke
riteria served as a guideline to define endocarditis, histologic
onfirmation was not performed, and thus thrombus and
brous casts may have been mistaken for vegetation. Further,
ome echocardiograms were unavailable for review and thus
epresent a source of potential false positive vegetations. In
ddition, our use of TEE to screen patients with localized lead
rosion discloses additional patients with intracardiac vegeta-
ions who may have been overlooked otherwise.
onclusions
s indications for device implantation expand, the prevalence
f device-related infections will increase. Vigilant recognition
nd aggressive management should be the pillars of therapy if
otentially fatal complications are to be avoided. Patients with
nfection and intracardiac vegetations represent a high-risk
opulation with multiple comorbidities and significant mortal-
ty regardless of management strategy. Our experience suggests
hat percutaneous lead extraction, when performed by experi-
nced operators, using standard techniques is both safe and
easible in patients with intracardiac vegetations up to 4 cm.
either the causative microorganism nor the presence of
ntracardiac vegetations impacts the time required for lead
xtraction. Additionally, reimplantation of CRM devices is
tytion Mortality
Comments
Death related to sepsis
Deaths related to sepsis
Deaths related to sepsis; post-operative mortality 7.6%;
30% septic embolization
Post-operative period defined as 8 days; IE proven by histology;
overall mortality 24%
U.S. lead extraction database
Deaths related to sepsis and heart failure; 12 patients had vegetations 1 cm
Total laser experience in U.S. (1995–99)
12.5% “surgical” mortality includes surgical and percutaneous approaches
Death from sepsis; 55% septic emboli
90% with IE; mean vegetation size 1.3 cm; deaths related to sepsis
7 deaths during IH, only 2 procedure related;
5 deaths (11%) due to sepsis in 23% with IE
Long-term survival between groups similar (p  0.11)
Limited data on 85 patients with IE
lmonary bypass; percutaneous extraction performed using current standard techniques. †Majorortalixtrac
or
tions†
%
%
%
%
%
%
%
%
%
rdiopu
related endocarditis.
al versus percutaneous mortality data).
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isease. Prospective randomized trials are needed to determine
ppropriate methods of surveillance for vegetations and timing of
evice reimplantation so relapse of infection can be minimized.
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